Share issue
2021
Oncopeptides has completed a directed share issue raising approximately SEK 1,106 million (USD 130 million)
March 10, 2021 – Regulatory press release
Oncopeptides AB (publ) announces that the Company has successfully completed a directed share issue raising approximately SEK 1,106 million in gross proceeds.
The board of directors of Oncopeptides has, based on the issue authorization granted by the annual general meeting on May 26, 2020, and as indicated in the Company’s press release on March 9 2021, resolved on a directed share issue of 7,000,000 new shares at a subscription price of SEK 158 per share (the “Directed Share Issue”), which means that the Company will receive gross proceeds of approximately SEK 1,106 million (approximately USD 130 million).
Oncopeptides intends to carry out a directed share issue
March 9, 2021 – Regulatory press release
Oncopeptides AB (publ) announces its intention to carry out a new share issue directed to Swedish and international institutional investors (the “Directed Share Issue”). The Company has retained Carnegie, Cowen, DNB Markets, JP Morgan and Kempen & Co to act as Joint Bookrunners (the “Joint Bookrunners”) in connection with the Directed Share Issue.
The subscription price and the total number of new shares in the Directed Share Issue will be determined by way of an accelerated bookbuild process (the “Bookbuilding”). It is intended that the number of newly issued shares will amount to approximately 10 percent of the total number of shares in the Company. Bookbuilding will start immediately following this announcement.